AFP and hepatocellular carcinoma: Currently, DCP is considered as a phase II biomarker, which is more specific than total AFP level in detecting HCC and more reliable than AFP as a prognostic tool for HCC recurrence and patient survival after hepatectomy, liver transplantation, radio-frequency ablation, and TACE treatment [94].